Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer

A cancer treatment and therapeutic agent technology, applied in the field of differentially expressed tumor-specific polypeptides for cancer diagnosis and treatment, can solve the problems of expensive, narrow detection application range, and inability to detect other types of cancer

Inactive Publication Date: 2007-01-24
GENMAB AS
View PDF12 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although these markers are being used to detect a variety of cancers, the disadvantage of these markers is that they detect advanced rather than early cancers
[0004] In addition, many commercially available tests can only be applied to a very narrow range of non-steroid-dependent cancers, meaning that the tests often fail to detect other types of cancer
In addition, the narrow range of application of these tests means that it may be necessary to perform multiple tests on a single patient for these diagnostic purposes
Multiple testing is expensive and there is a high risk that one of the many testing methods may produce a false positive test result

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer
  • Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer
  • Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0163] Example 1. Labeling method for isolating RNA and cDNA from colon tissue

[0164] The identification of disease-specific molecular markers is extremely important for the diagnosis and treatment of various types of steroid-independent cancers, especially those arising from neoplastic transformations of epithelial cells. A prerequisite for the successful identification of molecular-based differences between tumor tissues and those isolated from healthy individuals lies in the comparative transcriptional analysis of differentially regulated genes in epithelial cells isolated from healthy and tumorigenic tissues.

[0165] For this purpose, tissue samples were collected from colon cancer patients at different stages of the disease, together with healthy colon tissue collected from distant sites (sample sets). In Cottbus (Carl-Thiem-Klinikum Cottbus, Chirurgische Klinik, 03048 Cottbus, Germany), Magdeburg (Otto-von-Guericke-Klinik, Leipziger Strasse44, 39120 Magdeburg, Germany...

Embodiment 2

[0170] Example 2. Data Analysis Using Rosetta Resolver (Rosetta Inpharmatics. Kirkland, WA)

[0171]Expression of genes encoding plasma membrane proteins or plasma membrane-associated proteins was studied using the Rosetta Resolver platform (Rosetta Inpharmatics. Kirkland, WA). Using the publicly available LocusLink database (NCBI), the gene names and database identifiers of all extracted genes encoding known plasma membrane proteins or plasma membrane-associated proteins were mapped to their presence on the human-1 cDNA microarray (Agilent Technologies, USA ) on the identified corresponding features. During the study period, 1147 coding sequences of 1480 known plasma membrane proteins or related proteins registered in LocusLink (NCBI) were present on the cDNA microarrays used. These 1147 genes were combined in Bioset within Rosetta Resolver (Agilent Technologies, USA) and their expression was analyzed in 15 colon samples (tumor and healthy samples). Protein-coding genes of ...

Embodiment 3

[0172] Example 3. Detection of Differential Gene Expression in Patients for Diagnostic Purposes

[0173] The expression pattern of immunogenic membrane proteins of the proteins of the invention can be analyzed by real-time quantitative RT (reverse transcription)-PCR (polymerase chain reaction) (ref). Briefly, total RNA from a minimum of 20 tumor and non-tumor pairs (isolated epithelial cells) and 3-4 different cell lines (controls for within-assay variation) of the tissue of interest were reversed in triplicate using random hexamers. Transcription, followed by parallel amplification by real-time quantitative PCR in the presence of SYBR Green I using primer pairs specific for the sequence of interest. These primers were designed using Applied Biosystems' PrimerExpress 2.0 software; they should span introns to avoid detection of contaminating DNA and should not be complementary to any other sequence in the human genome as detected by BLAST searches. Data were normalized using 2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to reagents and methods for the diagnosis, prognosis and treatment of cancer. Specifically, the present invention relates to the use of proteins encoding transmembrane superfamily member 6 (TM4SF6), synaptophysin-like protein (SYPL), stomatin-like 2 (STOML2), Ras-associated GTP-binding protein (RAGA), nucleotide-sensitive Chloride channel 1A (CLNS1A), prion protein (p27-30) (PRNP), guanine nucleotide-binding protein β2-like 1 (GNB2L1), guanine nucleotide-binding protein 4 (GNG4), integral membrane protein 2B (ITM2B), integral membrane protein 1 (ITM1), transmembrane 9 superfamily member 2 (TM9SF2), opiate receptor-like 1 protein (OPRL1), low-density lipoprotein receptor-related protein 4 (LRP4), human kidney Nucleic acid and amino acid sequences of glomerular epithelin 1 (GLEPP1), toll-like receptor 3 (TLR3), and / or zona pellucida glycoprotein 3A (ZP3) for early and advanced non-steroid-specific cancer diagnosis, cancer prognosis, and For screening therapeutic agents that modulate the gene expression and / or biological activity of the protein. The invention further relates to biotechniques designed to inhibit gene expression and / or biological activity of said proteins, including the use of agents identified in the screening assays described herein, vector delivery of antisense polynucleotide sequences, and the Antibody targeting the protein. In specific embodiments, the protein is of human origin.

Description

[0001] The present invention relates to reagents and methods for the diagnosis, prognosis and treatment of cancer. Specifically, the present invention relates to the use of proteins encoding transmembrane superfamily member 6 (TM4SF6), synaptophysin-like protein (SYPL), stomatin-like 2 (STOML2), Ras-associated GTP-binding protein (RAGA), nucleotide-sensitive Chloride channel 1A (CLNS1A), prion protein (p27-30) (PRNP), guanine nucleotide-binding protein β2-like 1 (GNB2L1), guanine nucleotide-binding protein 4 (GNG4), integral membrane protein 2B (ITM2B), integral membrane protein 1 (ITM1), transmembrane 9 superfamily member 2 (TM9SF2), opiate receptor-like 1 protein (OPRL1), low-density lipoprotein receptor-related protein 4 (LRP4), human kidney Nucleic acid and amino acid sequences of glomerular epithelin 1 (GLEPP1), toll-like receptor 3 (TLR3), and / or zona pellucida glycoprotein 3A (ZP3) for diagnosis of early and advanced non-steroid-specific cancers, cancer prognosis, and sc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68G01N33/68G01N33/574
CPCC12Q2600/178G01N33/6893C12Q1/6886C12Q2600/158G01N2500/00G01N33/57407C12Q2600/106C12Q2600/136A61P1/00A61P17/00A61P35/00
Inventor T·布施曼N·-K·福蒂亚迪斯M·福赫斯S·黑姆T·伊利尼亚S·拉默J·莫伊尔K·罗特曼-科西克V·塞伯特S·T·佩雷斯K·斯戴荘斯基
Owner GENMAB AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com